 Connection
Mario Enrico Canonico to Platelet Aggregation Inhibitors
This is a "connection" page, showing publications Mario Enrico Canonico has written about Platelet Aggregation Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.861 |
|
|
|
-
Canonico ME, Parr J, Debus ES, Nehler MR, Patel MR, Anand SS, Svet M, Hess CN, Capell WH, Ycas J, Chen J, Szarek M, Muehlhofer E, Haskell LP, Berkowitz SD, Bauersachs RM, Bonaca MP. Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial. Circ Cardiovasc Interv. 2026 May; 19(5):e015229.
Score: 0.703
-
Canonico ME, Avvedimento M, Piccolo R, Hess CN, Bardi L, Ilardi F, Giugliano G, Franzone A, Gargiulo G, Berkowitz SD, Cannon CP, Esposito G, Bonaca MP. Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndrome: An Updated Review of Current Evidence. Clin Ther. 2025 Jul; 47(7):511-518.
Score: 0.661
-
Piccolo R, Laino A, Vitale AP, Canonico ME, Avvedimento M, Simonetti F, Paolillo R, Piaz FD, Charlier B, Spinelli A, Cristiano S, Serafino LD, Cirillo P, Gargiulo G, Franzone A, Filippelli A, Conti V, Esposito G. Sex differences among elderly ACS patients undergoing percutaneous coronary intervention receiving Ticagrelor 60 mg vs. 90 mg. J Thromb Thrombolysis. 2026 Mar; 59(3):551-563.
Score: 0.172
-
Gargiulo G, Cirillo P, Sperandeo L, Castiello DS, Manzi L, Forzano I, Florimonte D, Simonetti F, Canonico ME, Avvedimento M, Paolillo R, Spinelli A, Buongiorno F, Serafino LD, Spaccarotella CAM, Franzone A, Piccolo R, Stabile E, Valgimigli M, Esposito G. Pharmacodynamic effects of cangrelor in patients with acute or chronic coronary syndrome undergoing percutaneous coronary intervention: the POMPEII Registry. EuroIntervention. 2025 May 16; 21(10):560-570.
Score: 0.166
-
Piccolo R, Simonetti F, Avvedimento M, Cutillo M, Canonico ME, Conti V, Gargiulo G, Paolillo R, Dal Piaz F, Filippelli A, Charlier B, Spinelli A, Cristiano S, Cirillo P, Di Serafino L, Franzone A, Esposito G. Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial. Eur Heart J Cardiovasc Pharmacother. 2024 11 06; 10(7):578-587.
Score: 0.160
-
Canonico ME, Low Wang CC, Hsia J, Debus ES, Nehler MR, Patel MR, Anand SS, Ycas J, Capell WH, Muehlhofer E, Haskell LP, Berkowitz SD, Bauersachs R, Bonaca MP. Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization. J Am Coll Cardiol. 2024 Aug 27; 84(9):801-811.
Score: 0.158
-
Canonico ME, Hess CN, Secemsky EA, Bonaca MP. Antithrombotic Therapy in Patients Undergoing Peripheral Artery Interventions. Interv Cardiol Clin. 2024 10; 13(4):553-559.
Score: 0.158
-
Parodi G, Dossi F, Raccis M, Talanas G, Mura E, Siciliano R, Guarino S, Marini A, Franca P, Saba PS, Sanna GD, Canonico ME. Platelet inhibition with orodispersible ticagrelor in acute coronary syndromes according to morphine use: the TASTER study final results. Eur Heart J Cardiovasc Pharmacother. 2023 12 14; 9(8):692-700.
Score: 0.151
-
Scudiero F, Valenti R, Marcucci R, Sanna GD, Gori AM, Migliorini A, Vitale R, Giusti B, De Vito E, Corda G, Paniccia R, Zirolia D, Canonico ME, Parodi G. Platelet Reactivity in Hepatitis C Virus-Infected Patients on Dual Antiplatelet Therapy for Acute Coronary Syndrome. J Am Heart Assoc. 2020 09 15; 9(18):e016441.
Score: 0.120
-
Siciliano R, Canonico ME, Talanas G, Saba PS, Parodi G. Cangrelor-supported primary percutaneous coronary intervention in a patient with cardiogenic shock due to left main acute occlusion. J Cardiovasc Med (Hagerstown). 2020 Aug; 21(8):616-617.
Score: 0.119
-
Gargiulo G, Narciso V, Forzano I, Sperandeo L, Castiello DS, Simonetti F, Manzi L, Florimonte D, Canonico ME, Avvedimento M, Paolillo R, Spinelli A, Di Serafino L, Spaccarotella CAM, Franzone A, Piccolo R, Stabile E, Cirillo P, Valgimigli M, Esposito G. Pharmacodynamic effects of cangrelor in patients with or without STEMI undergoing percutaneous coronary intervention: insights from the POMPEII study. Eur Heart J Acute Cardiovasc Care. 2026 Jul 08; 15(7):524-534.
Score: 0.045
-
Muscoli S, Cimmino G, Canonico ME, Cesaro A, De Rosa G, De Rosa S, Coronelli MM, Natale F, Perrone MA, Sticchi A, Sorrentino S, Sucato V, Renda G, Paolillo S, Indolfi C, Calabrò P, Perrone Filardi P, Cirillo P. Comprehensive insights into peripheral artery disease: an overview from the working groups of pathogenesis of atherosclerosis and thrombosis of the Italian Society of Cardiology. J Cardiovasc Med (Hagerstown). 2025 07 01; 26(7):325-338.
Score: 0.042
-
Morrison JT, Canonico ME, Anand SS, Patel MR, Debus ES, Nehler MR, Hess CN, Hsia J, Capell WH, Muehlhofer E, Haskell LP, Berkowitz SD, Bauersachs RM, Bonaca MP. Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD. Circulation. 2024 May 07; 149(19):1536-1539.
Score: 0.039
-
Gargiulo G, Marenna A, Sperandeo L, Manzi L, Avvedimento M, Simonetti F, Canonico ME, Paolillo R, Spinelli A, Borgia F, Diserafino L, Franzone A, Stabile E, Piccolo R, Cirillo P, Valgimigli M, Esposito G. Pharmacodynamic effects of cangrelor in elective complex PCI: insights from the POMPEII Registry. EuroIntervention. 2023 03 20; 18(15):1266-1268.
Score: 0.036
-
Scudiero F, Canonico ME, Sanna GD, Dossi F, Silverio A, Galasso G, Esposito G, Porto I, Parodi G. Dual Antiplatelet Therapy with 3rd Generation P2Y12 Inhibitors in STEMI Patients: Impact of Body Mass Index on Loading Dose-Response. Cardiovasc Drugs Ther. 2023 08; 37(4):695-703.
Score: 0.033
-
Piccolo R, Avvedimento M, Canonico ME, Gargiulo P, Paolillo R, Conti V, Dal Piaz F, Filippelli A, Morisco C, Simonetti F, Leone A, Marenna A, Bruzzese D, Gargiulo G, Stabile E, Di Serafino L, Franzone A, Cirillo P, Esposito G. Platelet Inhibition with Ticagrelor 60 mg Versus 90 mg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial. Cardiovasc Drugs Ther. 2023 10; 37(5):1031-1038.
Score: 0.033
-
Parodi G, Talanas G, Mura E, Canonico ME, Siciliano R, Guarino S, Marini A, Dossi F, Franca P, Raccis M, Saba PS, Sanna GD. Orodispersible Ticagrelor in Acute Coronary Syndromes: The TASTER Study. J Am Coll Cardiol. 2021 07 20; 78(3):292-294.
Score: 0.032
-
Santoro C, Capone V, Canonico ME, Gargiulo G, Esposito R, Sanna GD, Parodi G, Esposito G. Single, Dual, and Triple Antithrombotic Therapy in Cancer Patients with Coronary Artery Disease: Searching for Evidence and Personalized Approaches. Semin Thromb Hemost. 2021 Nov; 47(8):950-961.
Score: 0.032
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|